Sistemic Announces Customer Agreement with Cytori Therapeutics
Sistemic Ltd. ("Sistemic"), a leading provider of microRNA-based problem-solving services and kit-based products, has fo…
Sistemic Ltd. ("Sistemic"), a leading provider of microRNA-based problem-solving services and kit-based products, has fo…
Cytori Therapeutics (NASDAQ: CYTX) has obtained approval to sell the Celution® 800 System in Russia for various medical…
During the first quarter of 2012, Cytori Therapeutics (NASDAQ: CYTX) advanced its cardiac cell therapy product pipeline,…
Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of RESTORE-2 trial results in the peer-reviewed Europ…
In 2011, Cytori Therapeutics (NASDAQ: CYTX) achieved important objectives towards validating Celution® technology in mul…
Cytori Therapeutics (NASDAQ: CYTX) has received an Investigational Device Exemption (IDE) approval from the U.S. FDA to…
Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of previously reported six-month outcomes from APOLLO…
Cytori's (NASDAQ: CYTX) Celution® One System, the next-generation device of the Company's Celution® platform, has been g…
Cytori Therapeutics (NASDAQ: CYTX) today is reporting its third quarter 2011 business update and financial results.…
Cytori Therapeutics (NASDAQ: CYTX) has entered into a Celution® System agreement with Apollo Hospitals, one of Asia's la…